Patents by Inventor Javier Blanc
Javier Blanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190152922Abstract: The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.Type: ApplicationFiled: August 23, 2018Publication date: May 23, 2019Inventors: Christel Jeanne Marie MENET, Oscar MAMMOLITI, Javier BLANC, Mislav ORSULIC, Maja ROSCIC
-
Patent number: 10206907Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: August 15, 2016Date of Patent: February 19, 2019Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Javier Blanc, Nolwenn Jouannigot, Alastair James Hodges, Koen Kurt Smits
-
Patent number: 10179771Abstract: The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.Type: GrantFiled: September 12, 2016Date of Patent: January 15, 2019Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Oscar Mammoliti, Javier Blanc, Mislav Orsulic, Maja Roscic
-
Publication number: 20170057928Abstract: The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.Type: ApplicationFiled: September 12, 2016Publication date: March 2, 2017Inventors: Christel Jeanne Marie MENET, Oscar MAMMOLITI, Javier BLANC, Mislav ORSULIC, Maja ROSCIC
-
Publication number: 20170035738Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: ApplicationFiled: August 15, 2016Publication date: February 9, 2017Inventors: Christel Jeanne Marie MENET, Luc Juliaan Corina VAN ROMPAEY, Stephen Robert FLETCHER, Javier BLANC, Nolwenn JOUANNIGOT, Alastair James HODGES, Koen Kurt SMITS
-
Patent number: 9505754Abstract: A compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.Type: GrantFiled: August 4, 2014Date of Patent: November 29, 2016Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Javier Blanc
-
Patent number: 9440929Abstract: The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.Type: GrantFiled: January 19, 2015Date of Patent: September 13, 2016Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Oscar Mammoliti, Javier Blanc, Mislav Orsulic, Maja Roscic
-
Patent number: 9415037Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: October 6, 2014Date of Patent: August 16, 2016Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Javier Blanc, Nolwenn Jouannigot, Alastair James Hodges, Koen Kurt Smits
-
Publication number: 20150203455Abstract: The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.Type: ApplicationFiled: January 19, 2015Publication date: July 23, 2015Inventors: Christel Jeanne Marie MENET, Oscar MAMMOLITI, Javier BLANC, Mislav ORSULIC, Maja ROSCIC
-
Patent number: 9062051Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and their use in the prophylaxis and/or treatment of inflammatory conditions, type 2 diabetes, neurological and/or neurodegenerative diseases, autoimmune diseases, proliferative diseases (in particular metastatic diseases, and/or cancer), abnormal angiogenesis associated diseases, degradation of cartilage, and/or disruption of cartilage homeostasis, in particular in the prophylaxis and/or treatment of cancer. The present invention also discloses methods of treatment using the same compounds, for the prophylaxis and/or treatment of said diseases by administering the compound of the invention.Type: GrantFiled: August 18, 2014Date of Patent: June 23, 2015Assignee: GALAPAGOS NVInventors: Laurent Raymond Maurice Sanière, Jacques Huck, Graeme James Dykes, Benoit Antoine Schmitt, Javier Blanc, Anna Sara Butler, Florence Marie-Emilie Bonnaterre, Stéphane Nicolas Alain Beaumont
-
Publication number: 20150150856Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: ApplicationFiled: October 6, 2014Publication date: June 4, 2015Inventors: Christel Jeanne Marie MENET, Luc Juliaan Corina VAN ROMPAEY, Stephen Robert FLETCHER, Javier BLANC, Nolwenn JOUANNIGOT, Alastair James HODGES, Koen Kurt SMITS
-
NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
Publication number: 20150080391Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and their use in the prophylaxis and/or treatment of inflammatory conditions, type 2 diabetes, neurological and/or neurodegenerative diseases, autoimmune diseases, proliferative diseases (in particular metastatic diseases, and/or cancer), abnormal angiogenesis associated diseases, degradation of cartilage, and/or disruption of cartilage homeostasis, in particular in the prophylaxis and/or treatment of cancer. The present invention also discloses methods of treatment using the same compounds, for the prophylaxis and/or treatment of said diseases by administering the compound of the invention.Type: ApplicationFiled: August 18, 2014Publication date: March 19, 2015Inventors: Laurent Raymond Maurice SANIÈRE, Jacques HUCK, Graeme James DYKES, Benoit Antoine SCHMITT, Javier BLANC, Anna Sara BUTLER, Florence Marie-Emilie BONNATERRE, Stéphane Nicolas Alain BEAUMONT -
Publication number: 20150031671Abstract: A compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.Type: ApplicationFiled: August 4, 2014Publication date: January 29, 2015Inventors: Christel Jeanne Marie MENET, Javier BLANC
-
Patent number: 8853240Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: July 24, 2009Date of Patent: October 7, 2014Assignee: Galapagos NVInventors: Christel Jeanne Marie Menet, Nolwenn Jouannigot, Javier Blanc, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Alastair James Hodges, Koen Kurt Smits
-
Patent number: 8796457Abstract: A compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.Type: GrantFiled: June 25, 2010Date of Patent: August 5, 2014Assignee: Galapagos NVInventors: Christel Jeanne Marie Menet, Javier Blanc
-
Publication number: 20120309784Abstract: A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: ApplicationFiled: August 10, 2012Publication date: December 6, 2012Inventors: Christel Jeanne Marie MENET, Javier BLANC
-
Patent number: 8242274Abstract: A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: July 24, 2009Date of Patent: August 14, 2012Assignee: Galapagos NVInventors: Christel Jeanne Marie Menet, Javier Blanc
-
Publication number: 20110190260Abstract: [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.Type: ApplicationFiled: July 24, 2009Publication date: August 4, 2011Inventors: Christel Jeanne Marie Menet, Nolwenn Jouannigot, Javier Blanc, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Alastair James Hodges, Koen Kurt Smits
-
Publication number: 20100331359Abstract: A compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.Type: ApplicationFiled: June 25, 2010Publication date: December 30, 2010Inventors: Christel Jeanne Marie MENET, Javier Blanc
-
Publication number: 20100069607Abstract: A glycopeptide of the formula S-L-X—P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R1 and R3 are independently selected from H or Ac, R4 is Ac, and R2 is a group of formula IV, wherein R7 and R8 are each independently selected from an optionally protected monosaccharide and an optionally protected polysaccharide, A, B, C and D are each independently 1 or 2, and m is 1 to 5; -L- is a moiety of the formula III wherein R5 and R6 are independently selected from H and Me and n is 1 to 3; and P is a peptide chain containing at least one amino acid having on its side chain the atom X, wherein X is an oxygen, a sulphur atom or a —CH2— moiety.Type: ApplicationFiled: June 29, 2007Publication date: March 18, 2010Applicant: UCL BUSINESS PLCInventors: Derek MacMillan, Javier Blanc